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Abstract 
Obesity is accompanied with a low-grade inflammation, which drives the risk to 
develop hepatocellular carcinoma (HCC). In this context, macrophages in the obese 
adipose tissue release cytokines e.g. IL-6 into the circulation. Ultimately, this causes 
systemic and chronic elevated IL-6 levels in obese individuals. IL-6 acts via the IL-6 
receptor and the co-receptor GP130. Downstream signaling activates STAT3 that in 
turn negatively feeds back via the inhibitor SOCS3 to tightly control IL-6 signaling. 
Under obese conditions, basal phosphorylated STAT3 levels are elevated in 
hepatocytes, but the responsiveness to acute IL-6 is diminished. A condition we refer 
to as IL-6 resistance. In this study different mouse models were generated to better 
understand the role of IL-6 resistance in HCC. Elevated levels of basal activated 
STAT3 and increased expression of Socs3 verified hepatic IL-6 resistance in obese 
mice. To prevent hepatic IL-6 resistance, a liver specific Socs3 knockout mouse was 
generated that surprisingly failed to prevent the development of an IL-6 resistance, 
presumably due to compensatory Socs1 expression. While insulin sensitivity was still 
improved in 11 weeks old DEN-injected hepatic Socs3 knockout mice, these mice 
developed IL-6 resistance at later stages and ultimately developed similar HCC 
burden compared to their controls. To further understand the contribution of 
compensatory SOCS1 in IL-6 resistance, we currently aim at generating a conditional 
knockout and reporter allele of Socs1 that will be intercrossed with the Socs3 
conditional allele to prevent IL-6 resistance. To induce hepatic IL-6 resistance 
genetically, a mouse model of constitutively active GP130 (LGP130) was used. 
Lgp130 was expressed in hepatocytes and these mice were subjected to DEN-
induced hepatocarcinogenesis. These mice developed a similar number, but 
significantly larger tumors, thus revealing a role of IL-6 resistance in tumor 
progression rather than development. Hepatic IL-6 resistance exhibited polarizing 
effects on liver macrophages via CSF-1 and inducible depletion of the Csf-1r in 
macrophages ameliorated HCC progression in obese mice presumably via triggering 
macrophage polarization towards an M2 state. 
To further dissect hepatic IL-6 resistance on HCC progression, a novel ROSA26 
allele was generated, allowing for hepatocyte-specific overexpression of Socs3 that 
is currently under investigation. Collectively, this study successfully introduces novel 
genetically engineered mouse models to examine the role of IL-6 resistance in HCC 
development and progression. 
